NIKKEI 225
38,385.73 +29.67 (+0.08%) HANG SENG
19,073.71 -41.35 (-0.22%) CRUDE OIL
78.56 +0.54 (+0.69%) GOLD FUTURES
2,393.40 +33.50 (+1.42%) DOW
39,842.66 +284.55 (+0.72%) Bitcoin GBP
51,432.28 +3,026.89 (+6.25%)
Coloplast A/S (CBHD.DE)
| Previous close | 113.50 |
| Open | 112.15 |
| Bid | 111.80 x 200000 |
| Ask | 112.70 x 7800 |
| Day's range | 110.85 - 112.50 |
| 52-week range | 92.50 - 130.95 |
| Volume | |
| Avg. volume | 340 |
| Market cap | 24.92B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | 37.31 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.82 (2.48%) |
| Ex-dividend date | 13 May 2024 |
| 1y target est | N/A |
- GuruFocus.com
Coloplast A/S's Dividend Analysis
Coloplast A/S (CLPBY) recently announced a dividend of $0.23 per share, payable on 2023-12-22, with the ex-dividend date set for 2023-12-08. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into Coloplast A/S's dividend performance and assess its sustainability.
- Reuters
Coloplast buys fish skin woundcare firm for up to $1.3 billion
COPENHAGEN (Reuters) -Coloplast has agreed to buy Iceland-based Kerecis, a biologic wound care firm that uses fish skin to develop tissue-transplant products, for up to $1.3 billion, the Danish medical equipment maker said on Friday. Coloplast said it would finance the deal by raising equity. "Kerecis represents an attractive opportunity to strategically strengthen Coloplast's presence in the advanced wound care market by entering the high-growth, U.S.-centric biologics segment," the Danish firm said in a statement.
